Media stories about Covance (NYSE:CVD) have been trending somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Covance earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned news headlines about the healthcare company an impact score of 47.51653919012 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Shares of Covance (CVD) remained flat at $$107.07 during trading on Friday.

WARNING: “Covance (CVD) Receives Daily Media Impact Score of 0.14” was first posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of US and international copyright laws. The legal version of this news story can be accessed at https://www.watchlistnews.com/covance-cvd-receives-daily-media-impact-score-of-0-14/1724649.html.

Covance Company Profile

Covance Inc is engaged in drug development services. The Company provides a range of early-stage and late-stage product development services to the pharmaceutical and biotechnology industries. The Company also provides laboratory testing services to the chemical, agrochemical and food industries. The Company operates in two segments: early development services, and late-stage development services.

Insider Buying and Selling by Quarter for Covance (NYSE:CVD)

Receive News & Ratings for Covance Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Covance Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.